Showing results (201-210 of 260) with videos related to
Sort By:
Pageof 26
Gastroenterology|November 1, 1980
Cimetidine spares the glucuronidation of lorazepam and oxazepamR V Patwardhan, G W Yarborough, P V Desmond, et al.Hepatology (Baltimore, Md.)|February 1, 1990
The effect of liver dysfunction on colchicine pharmacokinetics in the ratJ A Leighton, M K Bay, A L Maldonado, et al.British Journal of Clinical Pharmacology|June 20, 2003
Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with CaucasiansP Dalén, M-L Dahl, H-K Roh, et al.Clinical Pharmacology and Therapeutics|August 17, 2000
CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphismC Wandel, J S Witte, J M Hall, et al.The Journal of Pharmacology and Experimental Therapeutics|November 24, 1999
Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activityR B Kim, B Leake, M Cvetkovic, et al.Molecular Pharmacology|October 1, 1994
Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in JapaneseS M De Morais, G R Wilkinson, J Blaisdell, et al.The Journal of Pharmacology and Experimental Therapeutics|March 1, 1984
Influence of genetic polymorphism on the metabolism and disposition of encainide in manT Wang, D M Roden, H T Wolfenden, et al.The Journal of Biological Chemistry|June 3, 1994
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humansS M de Morais, G R Wilkinson, J Blaisdell, et al.The Journal of Pharmacology and Experimental Therapeutics|September 1, 1985
Phenotypic differences in mephenytoin pharmacokinetics in normal subjectsP J Wedlund, W S Aslanian, E Jacqz, et al.Diabetologia|August 1, 1980
Metabolic effects and pharmacokinetics of intravenously administered dichloroacetate in humansP G Wells, G W Moore, D Rabin, et al.Pageof 26